Podcasts about insitro

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. The FDA is planning to fully integrate AI into their decision-making process by June 30, with individual centers starting the rollout immediately. Sanofi has cut off its antibody partner, leading to an 80% reduction in headcount at IgM Biosciences. The FDA has faced delays, including missing review dates for GSK's Nucala. President Trump is expected to unveil a drug pricing plan on Monday that has been criticized by big pharma and patient groups. Lotte Biologics offers end-to-end services for ADC manufacturing in Syracuse, NY. Rallybio, Insitro, Shape, and Vor have all downsized their workforces.

Daphne Koller is an AI pioneer, MacArthur fellow, member of the National Academy of sciences and the founder and CEO of drug discovery and development company insitro. She'll talk about how attitudes surrounding AI have evolved in her multi-decade career and what's ahead - including how technology is reshaping drug discovery, paving the way for more targeted treatments for the patients who can benefit most. But maximizing AI-powered innovation will depend on better investments in data aggregation, quality and collection and navigating hype cycles that can distract from real impact.  This academic-turned-entrepreneur will also share how founding insitro (and a previous company, Coursera) helped her expand her leadership and management skills, all while driving home the importance of shaping a company culture. At insitro, this focus building a culture that works for unique needs led to a special ‘helix' inspired-structure that helps discovery biologists, automation engineers and others in the company's cross-functional teams keep communication flowing, problem solve, and prevent the siloes that can hold true innovation back.  Transcript: Insitro: Top Ten Technologies of 2024:

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.This week's commercialization news includes updates on Zepbound supply, Enjaymo's new home, and expanding access to HIV drugs. Medicare has tweaked rules for drug price talks, while GSK reports that its RSV vaccine protects against disease over three seasons. GSK's Viiv plans to expand the supply of HIV drugs in Africa, and Sanofi's rare disease drug finds a new home at Recordati. Other news includes a protein prediction winning the Chemistry Nobel and Alnylam submitting an important drug application. Trends suggest that biosimilars may make a mark in 2025, with incentives favoring them in the Medicare market. Protein prediction wins the Chemistry Nobel Prize, Alnylam submits a crucial drug application, Lilly partners with AI specialist Insitro to develop metabolic medicines, and Purespring raises $105 million for gene therapy for kidney disease. AI startup Basecamp allies with The Broad Institute to create 'programmable' genetic medicines. Additionally, Lilly appoints Mount Sinai scientist Thomas Fuchs as its first Chief AI Officer to lead AI initiatives in drug discovery and clinical trials. Other news includes J&J closing a cancer study, Alnylam seeking approval for a potential blockbuster drug, and Propharma receiving a regulatory and compliance award at CPhI.The Supreme Court declined to review a Texas abortion case related to emergency care, a blow to the Biden administration's efforts. A survey found that nearly 70% of healthcare organizations affected by cyberattacks experienced disruptions in patient care. Steward Health Care is auctioning off assets, including closing Norwood Hospital in Massachusetts. Baxter reported no structural damage at their North Carolina site affected by Hurricane Helene. The payer-provider relationship in healthcare is becoming more complex with consolidation and value-based care, leading to tensions over reimbursement and access.Kezar's lupus trial has been put on hold after four patient deaths, making it a potential buyout target. Investor Kevin Tang is interested in acquisition. Big pharma is also investing in cell and gene therapies, with companies like Lilly and Sanofi making moves in the industry. The Genscript Biotech Global Forum 2025 is coming up on January 15, offering a platform to discuss innovations and challenges in gene and cell therapy. Additionally, Lilly's obesity clinical program faces challenges, while Stealth's ultrarare disease candidate may not meet approval standards.Eli Lilly's obesity program is highlighted as a key factor in the company's dominance in the industry, with CEO David Ricks confident in their position. Wuxi Biologics faces uncertainty in the U.S. after setbacks, while big pharma companies show growing interest in cell and gene therapy. Five radiopharma biotechs are identified as potential buyout targets, and Trilink Biotechnologies introduces custom sets of mRNA for screening studies. Other news includes increased investment in cell and gene therapy, activist investor Starboard's stake in Pfizer, and Merck's success with Keytruda in head and neck cancer. AstraZeneca puts $2 billion towards heart disease drugs, Sanofi offloads a rare autoimmune drug, and AbbVie trims earnings guidance.

Hello folks and welcome to This Is Robotics. I'm your host and fellow companion, Tom Green.The last half of 2024 is upon us, robotics-driven automation is in rapid ascendancy once again, especially now since 2024 is showing how robotics engages with GenAI, and how prompt engineering is significantly increasing the ease of adoption for robots everywhere. Last month, we gave you a longish one-hour show, which was necessary for it was meant to support my keynote address at SuperTechFT in San Francisco.  If you have yet to listen to it, it's Episode # 31 and deals with how quickly computer code has capitulated to prompt engineering…and why. Plus, the new breed of workers on the rise who are being hailed as the “New Collar” generation of workers.This month, we are listening to our global fans for feedback. We have a global fan base in 68 countries according to Buzzsprout stats. A fangirl Celina from the Philippines wants us to reprise a woman's show. Specifically, the rise of Alice Zhang (Verge Genomics) and her pursuit of answers to neurodegenerative diseases like Alzheimer's, Parkinson's, and ALS. Thank you, Celina for also pointing out how this story highlights how human insight creates the technical challenge and how LLMs are then employed to reveal a way forward for bio research. For Alice, it was robotics and LLMs cracking the code for ALS.During Alice's piece, she laments how broken bio research is and why. Which leads to our second fan request from Martin in Augsburg, Germany, who was fascinated with robotics in bio labs working with AI in what he calls Pharma 4.0. New drug research and discovery companies with strange, new names like Recursion Pharmaceuticals, Arctoris, Insitro, Relay Therapeutics, and Insilico Medicine are forging the way. Martin, good pick.We lead off this month humankinds almost innate fascination and attraction to humanoid robots. Why is that? We let a half dozen experts offer up some truly interesting insights and theories on just why that is. Those insights are wrapped up in a show about human attraction to robots where we commemorate National Kiss & Make up Day which is coming up in August.Okay, strap on your earphones or pop in your earbuds, which Buzzsprout tells us 3,000 people do daily worldwide to listen to This Is Robotics. We're thrilled you can join us today. Thanks and welcome.https://asianroboticsreview.com/home591-html

Artificial intelligence has the potential to massively improve human health: from developing new drugs to providing more accurate diagnoses and helping people who live with severe disabilities. But AI also has the potential, if used wrongly or governed badly, to make life worse for people dealing with health problems. In this episode, we hear from people on the front lines of the technology. Speakers: Victor Pineda, president and founder of the Victor Pineda Foundation/World ENABLED Alexandra Reeve Givens , CEO, Center for Democracy and Technology Chris Mansi, CEO, Viz.ai Daphne Koller, founder and CEO of Insitro Links: Centre for the Fourth Industrial Revolution: https://centres.weforum.org/centre-for-the-fourth-industrial-revolution/home AI Governance Alliance: https://initiatives.weforum.org/ai-governance-alliance/home Centre for Health and Healthcare: https://centres.weforum.org/centre-for-health-and-healthcare/ Related podcasts: AI: Is 2024 the year that governance catches up with the tech? What's next for generative AI? Three pioneers on their Eureka moments Quality over quantity: why the time has come for 'value based health care' Special Meeting 2024: Bridging the Health Gap Special Meeting 2024: AI Powered Industries Check out all our podcasts on wef.ch/podcasts: YouTube: - https://www.youtube.com/@wef/podcasts Radio Davos - subscribe: https://pod.link/1504682164 Meet the Leader - subscribe: https://pod.link/1534915560 Agenda Dialogues - subscribe: https://pod.link/1574956552 Join the World Economic Forum Podcast Club: https://www.facebook.com/groups/wefpodcastclub

Duane Valz has led the legal and IP functions at prominent Silicon Valley companies operating at a variety of scales and growth stages. He has been broadly recognized over the past 10 years as one of the world's leading IP strategists. Duane is currently VP & General Counsel of Insitro, a venture-backed company applying machine learning and automation to disease target identification and new drug development. Prior to Insitro, he was VP & General Counsel of Zymergen Inc., a molecular technology growth company operating at the intersection of biology, chemistry, automation and machine learning. Duane was previously a senior member of the Patent Team at Google, where he led strategic IP initiatives bearing on mobile, cloud, web, and open source technologies. He was also previously Associate General Counsel in charge of patent development at Yahoo! Duane began his career at Howard Rice Nemerovski Canady Falk & Rabkin (now combined with Arnold & Porter LLP). Duane serves on the Board of Directors for SMASH.org, is an advisory board member for UCOP's MESA program, and is on the advisory Board for the National Society of Black Physicists — all organizations focused on supporting underrepresented students in the pursuit of educations and careers in STEM fields. In this episode we dive deep into a topic that's been buzzing in the tech world – the corporate governance failure at OpenAI. We're peeling back the layers of what happened at OpenAI, exploring the intricate details of corporate governance, and the whirlwind of events that led to Sam Altman's surprising exit. Duane's insightful Medium article has set the stage, and now we're bringing it to life in an interactive session you won't want to miss! Here's a sneak peek of what we'll cover: The complexities of OpenAI's corporate structure and how it played a role in recent events. The dramatic aftermath of Altman's departure and its impact on the AI industry. Lessons in corporate governance and foresight for rapidly evolving tech companies. Whether you're a tech enthusiast, a governance guru, or just love a good corporate drama, this is the perfect opportunity to gain some valuable insights.

Matt continues his conversation with Katie Jackson, Senior Director of People & Organization Development at insitro for a talk about the future of work, in the new post-pandemic world.

Today's episode continues our coverage from a16z's recent AI Revolution event. You'll hear a16z Bio & Health GP Vijay Pande speak with Daphne Koller about the fascinating convergence of machine learning and genomics – two industries that have benefitted decades of investment and progress – which are now colliding head on.Daphne is a prominent innovator at this intersection, as a long-time professor in computer science at Stanford and co-founder of Coursera, who has decided to step back into the arena with her company Insitro. In fact, Insitro is a blend of in silico and in virto!If you'd like to access all the talks from AI Revolution in full, visit a16z.com/airevolution. Resources:Find Daphne on Twitter: https://twitter.com/DaphneKollerFind Vijay on Twitter: https://twitter.com/vijaypandeFind Insitro on Twitter: https://twitter.com/insitro Stay Updated: Find a16z on Twitter: https://twitter.com/a16zFind a16z on LinkedIn: https://www.linkedin.com/company/a16zSubscribe on your favorite podcast app: https://a16z.simplecast.com/Follow our host: https://twitter.com/stephsmithioPlease note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.

[0:59] Why life sciences?[3:42] AI in the life sciences[7:20] LLM for cells[11:55] Engineering disease and drug discovery[13:51] Bits vs. atoms[17:55] The opportunity aheadThis conversation is part of our AI Revolution series, recorded August 2023 at a live event in San Francisco. The series features some of the most impactful builders in the field of AI discussing and debating where we are, where we're going, and the big open questions in AI. Find more content from our AI Revolution series on www.a16z.com/AIRevolution.

Industry veteran and serial entrepreneur Daphne Koller tells In Vivo about how her company, Insitro, is unleashing the potential of computational biology and machine learning to discover new drug compounds.

Jacob sits down with Insitro CEO Daphne Koller to discuss founding Coursera, where and how ML can drive the most impact in drug development, and if foundation models can transform core drug discovery work and edtech.  (00:00) - intro (00:54) - Daphne's journey (09:18) - AI and biology discovery (10:59) - insitro vs. traditional pharma (20:04) - phenotyping patients (26:01) - early mistakes (29:51) - the future of data (35:33) - partnering with larger pharma companies (38:17) - impact of LLMs on biopharma (44:04) - over-hyped/under-hyped  With your co-hosts: @jasoncwarner - Former CTO GitHub, VP Eng Heroku & Canonical @ericabrescia - Former COO Github, Founder Bitnami (acq'd by VMWare) @patrickachase - Partner at Redpoint, Former ML Engineer LinkedIn @jacobeffron - Partner at Redpoint, Former PM Flatiron Health

Jacob sits down with Insitro CEO Daphne Koller to discuss founding Coursera, where and how ML can drive the most impact in drug development, and if foundation models can transform core drug discovery work and edtech. 00:00 intro00:59 Daphne's journey09:02 AI and biology discovery10:42 insitro vs. traditional pharma19:47 phenotyping patients25:44 early mistakes29:34 the future of data35:16 partnering with larger pharma companies38:00 impact of LLMs on biopharma43:47 over-hyped/under-hyped

In this episode, Daphne Koller, founder and CEO of insitro—as well as the co-founder of Coursera, a MacArthur Award winner, and a former professor in the department of computer science at Stanford University—chats with a16z Bio + Health founding partner Vijay Pande. Together, they talk about Daphne's career journey, how Daphne thinks about the last few decades of progress in AI, and how insitro leverages artificial intelligence and machine learning to explore biology through new models of discovery.

Life-saving therapeutics continue to grow more costly to discover. At the same time, recent advances in using machine learning for the life sciences and medicine are extraordinary. Are we on the verge of a paradigm shift in biotech? This week on the podcast, a pioneer in AI, Daphne Koller, joins Sarah Guo and Elad Gil on the podcast to help us explore that question. Daphne is the CEO and founder of Insitro — a company that applies machine learning to pharma discovery and development, specifically by leveraging “induced pluripotent stem cells.” We explain Insitro's approach, why they're focused on generating their own data, why you can't cure schizophrenia in mice, and how to design a culture that supports both research and engineering. Daphne was previously a computer science professor at Stanford, and co-founder and co-CEO of edutech company Coursera. Show Links:  Insitro - About  Video: AWS re:Invent 2019 – Daphne Koller of insitro Talks About Using AWS to Transform Drug Development  Sign up for new podcasts every week. Email feedback to show@no-priors.com Follow us on Twitter: @NoPriorsPod | @Saranormous | @EladGil | @DaphneKoller Show Notes:  [1:49] - How Daphne combined her biology and tech interests and ran a bifurcated lab at Stanford [4:34] - Why Daphne resigned an endowed chair at Stanford to build Coursera  [14:14] - How insitro approaches target identification problems and training data  [18:33] - What are pluripotent stem cells and how insitro identifies individual neurons  [24:08 ] - How insitro operates as an engine for drug discovery and partners to create the drugs themselves [26:48] - Role of regulations, clinical trials and disease progression in drug delivery  [33:19] - Building a team and workplace culture that can bridge both bio and computer sciences  [39:50] - What Daphne is paying attention to in the so-called golden age of machine learning   [43:12] - Advice for leading a startup in edtech and healthtech

Dr. Mary Rozenman, Chief Financial Officer and Chief Business Officer at insitro, and Dr. Chris Probert, senior machine learning scientist at insitro discuss how insitro's discovery process can start on either the clinical or cellular side, why scale is so important in every aspect of insitro's model, and why diversity of experience and background can be a powerful tool in solving hard problems.

Daphne Koller was a precociously clever child. She completed her first degree – a double major in mathematics and computer science – when she was just 17 and went on to become a distinguished Professor at Stanford University in California. But before long she'd given up this comfortable academic position to create the biggest online education platform in the world. In 2018, she founded the drug discovery company Insitro hoping to create a space where data scientists and molecular biologists could work together as equals. Daphne tells Jim Al-Khalili how a single question from her supervisor nudged her to use her considerable mathematical ability to do something useful and why she believes the time is right for artificial intelligence to discover new medicines. Producer: Anna Buckley

https://fellow.app/supermanagers/jevan-soo-lenox-insitro-building-a-cohesive-culture-how-you-bring-people-into-an-organization-is-how-you-set-them-up/ If the workplace culture isn't being lived, it doesn't really matter, does it? Managers are responsible for bringing the culture to life. Jevan Soo Lenox, Chief People Officer at Insitro, dives into the importance of building a cohesive culture across an organization and shares ways in how to do that. Jevan also shares the systems and processes he uses as a CPO and the importance of efficient onboarding for longterm success. Tune in to hear all about Jevan's leadership journey and the lessons learned along the way! . . . Like this episode? Be sure to leave a ⭐️⭐️⭐️⭐️⭐️ review and share the podcast with your colleagues.

About this Episode: This week's guest, Daphne Koller, is the Founder and CEO of Insitro - a company shifting the paradigm of new drug discovery using predictive models. Patrick and Daphne talk about why she founded Insitro, how to create unified datasets, and the importance of being realistic about drug discovery.

About this Episode: This week's guest, Daphne Koller, is the Founder and CEO of Insitro - a company shifting the paradigm of new drug discovery using predictive models. Patrick and Daphne talk about why she founded Insitro, how to create unified datasets, and the importance of being realistic about drug discovery.

Last month, roughly 5,000 liver community stakeholders gathered in London for the 2022 International Liver Congress (#ILC2022.) On Thursday afternoon, Scott Friedman chaired an abstract session discussing advances in the basic science of researching and understanding mechanisms surrounding fibrosis and stellate cells. Later, he described it as "one of the most exciting groups of presentations I've seen in many years." This conversation centers on papers with similar methods and processes for researching stellate cells.Scott begins this conversation by describing this process, which is based on another Nobel Prize-winning methodology. In this technique, the researchers start by forcing an adult mature skin cell (or any cell, for that matter) o express a cluster of very well-defined genes and transcription factors, which the researcher then turns into a generalized, Induced Pluripotent Stem (IPS) cell. Researchers have found ways to convert these IPS cells into stellate cells. The developer of this technique posited that it will enable us to explore the proteome. To Scott, this process of converting a generalized cell to a stellate cell we can analyze via proteomics to find new targets is more important and noteworthy than the result of this specific study (researchers identified a novel nuclear receptor called RORalpha). To quote Scott, "they're much closer to the action when they find a protein rather than just the mRNA that encodes it." He goes on to discuss a second study from Insitro (a company with which he consults) about their work seeking to optimize the IPS-derived stellate cells to find the one that most closely resembles cells in vivo. When Scott finishes, Neil notes that single-cell proteomics is not "coming, but it's not there yet." Neil anticipates we will have this pivotal tool available in a 1-2 year time horizon. Next, Jörn anticipates and asks about the next stage in the process: identifying a protein related to this process we can find in peripheral blood given that, as Neil noted, tissue sampling in the clinical setting will not be possible. Scott discusses a recent paper that seems to provide a solution to this issue in breast cancer. While he notes that the work has to be validated first, it clearly suggests researchers are close to finding proteins we can identify in blood in at least one cancer-related case. From there, Scott turns to Rachel for feedback, since this is the area in which her business is building its research. Her answer has several elements to it, but the main point is that proteomic development lags behind some of the other techniques but is making rapid advances as the costs of some key analytical processes come down. She then goes on to provide a description of epigenetics, the area in which she works most intensively.

Last month, roughly 5,000 liver community stakeholders gathered in London for the 2022 International Liver Congress (#ILC2022,) the first major hepatology Congress to be held in person since the start of the pandemic (smaller, but very valuable, meetings like NASH-TAG, LiverCONNECT and Paris NASH have taken place with an in-person component, but the International Liver Congress and The Liver Meeting have not). This episode focuses on an abstract session Scott Friedman chaired on Thursday afternoon discussing advancing in the basic science of researching and understanding mechanisms surrounding fibrosis.Scott starts by describing the session he co-chaired with Sophie Lotersztajn of INSERM as "one of the most exciting groups of presentations I've seen in many years." During this episode, he leads the rest of the panel through exploration of all six presentations. These include:--Targeting the liver circadian clock by REV-ERB-alpha activation improves liver fibrosis by circadian gating of TGF-beta signaling, Atish Mukherji, University of Strasbourg. Scott describes this presentation, which demonstrates that stellate cells have a circadian clock, as "one of the most surprising results" in that circadian activity can be linked to the  "lowly stellate cell."  This paper generated significant conversation among the group, ranging from Neil Henderson's observation that circadian regulation is a powerful regulator of fibrotic processes to Jörn Schattenberg's observations about what this might mean for treating patients in the clinic to Roger Green asking whether this concept might be germane to specific drugs in development (Scott had mentioned that signalling occurred through TGFbeta.  Louise Campbell and Rachel Zayas  add comments about the relevance of circadian rhythm to care today and ways this paper might yield exciting new areas for research.--Stellate cell dynamics in progression and regression of hepatic fibrosis, Laura Almale del Barrio, Denmark. This presentation, funded in part by Novo Nordisk, focused on how mouse livers respond when researchers stop injuring them. It leads Neil to comment on how little attention researchers pay to scar healing relative to how much more they pay to the process of scar creation and injury. In response to a question from Scott, Neil also discusses how advances in spatial transcriptomic will make questions like these easier to research in the not-too-distant future. After this, Jörn goes on to note that the paper discussed 14 different stellate cell states, which he interprets as involves activation and transitioning processes. He asks what this might imply for treating patients in the clinic.The other four presentations engender a similar level of exploration. They include:--Peroxidasin deficiency re-programs macrophages toward pro-fibrolysis function and promotes collagen resolution in liver, Mozhdeh Sojoodi, Mass General Hospital and Harvard. --Machine learning methods for detailed characterization of TGF-beta-induced signatures in a large iPSC-derived hepatic stellate cell cohort, Kara Marie Liu, Insitro, United States--The proteomic analysis of hepatic stellate cell differentiation from iPSCs identifies RORalpha as an antifibrogenic target, Raquel A. Martinez Garcia de la Torre, Spain--Biliary epithelial cell-specific RAGE controls ductular reaction-mediated fibrosis during cholestasis, Macrina Lam, GermanyIn each case, Scott starts by discussing the historic of scientific progress that predates the particular paper and topic, places the presentation properly within that context, and invites the others to comment. Each Surfer has unique (and uniquely interesting) comments in their own areas of expertise.

“We are now in a world where there is this an abundance of data, which is only the beginning to what we're likely to be able to see in the coming years. At the same time, we have this incredible set of machine learning methods [...]. This seems to be a moment in time when those two tidal waves are about to come together in a way that offers us the opportunity to unlock some of the underlying secrets and complexities that underlie human health and human disease.” This week we are sharing for posterity the discussion that Parker Moss, our Chief Commercial Officer, hosted earlier this month at the Genomics England Research Summit. Parker's discussion was with the world renowned Daphne Koller, the founder and CEO of insitro. Parker and Daphne explored the use of AI and machine learning in drug discovery and discussed the value of multimodal analysis. They also touched on some of the challenges of causal inference and target validation with unsupervised machine learning methodologies. Parker and Daphne then discussed the recent partnership between Genomics England and insitro.

Duane Valz has led the legal and IP functions at prominent Silicon Valley companies operating at a variety of scales and growth stages. He has been broadly recognized over the past 10 years as one of the world's leading IP strategists. Duane is currently VP & General Counsel of Insitro, a venture-backed company applying machine learning and automation to disease target identification and new drug development. Prior to Insitro, he was VP & General Counsel of Zymergen Inc., a molecular technology growth company operating at the intersection of biology, chemistry, automation and machine learning. Duane was previously a senior member of the Patent Team at Google, where he led strategic IP initiatives bearing on mobile, cloud, web, and open source technologies. He was also previously Associate General Counsel in charge of patent development at Yahoo! Duane began his career at Howard Rice Nemerovski Canady Falk & Rabkin (now combined with Arnold & Porter LLP). Duane serves on the Board of Directors for SMASH.org, is an advisory board member for UCOP's MESA program, and is on the advisory Board for the National Society of Black Physicists — all organizations focused on supporting underrepresented students in the pursuit of educations and careers in STEM fields. The assemblage of computing devices, sensors, cloud-based services, artificial intelligence and software applications that make up the internet have transformed our daily lives quite remarkably over the past 25 years. We enjoy connection, information, entertainment and host of conveniences with an ease and utility previously unimaginable. But along with those positives has come a shadow side that is increasingly concerning. This includes intrusive user tracking and targeting, secret government surveillance, cyber bullying, misinformation and distortions of history, election interference and voter manipulation, wide dissemination of conspiracies and violent ideologies, large scale cyber breaches, etc. Can Web 3 save us from the various ills that are afflicting the Internet? Its proponents suggest that a new approach to designing web services can help address many of the problems impacting internet users. In this discussion, Duane Valz will address the promise and possible shortcomings of Web 3. We'll also discuss what else might be needed to create a more positive internet experience going forward.

Over time, drug development has become more and more challenging.Success rates of clinical trials hover in the single digits, and the cost of developing a new treatment is greater than $2.5B.So, what can we do to make drug discovery faster, less expensive and more successful? How might advancements in machine learning and the availability of biomedical data revolutionize the drug design process?Daphne Koller is the CEO of Insitro, a company that is rethinking drug discovery using machine learning. She spent 18 years as a professor in the computer science department at Stanford before leaving to build the education platform Coursera. In 2016, Daphne returned to her passion for improving human health with machine learning, first as Chief Computing Officer at Calico Labs and then as the Founder of Insitro.On this episode of HLTH Matters, Daphne joins host Dr. Gautam Gulati to explain how her experience with her father's autoimmune condition informs her work and why we need to rethink the fundamental categorization of disease. Daphne describes how releasing machines from our preconceptions of what's important uncovers new science around the drivers of disease and serves as a critical starting point for developing new interventions. Listen in for Daphne's insight on leveraging machine learning to improve clinical trials and learn why data collection should be part of the fabric of every biopharma company.Topics CoveredDaphne's background in machine learning, biology and medical dataHow Daphne's experience with her father's autoimmune disease informs her work at InsitroWhy we need to rethink the fundamental categorization of what disease isDaphne's insight on the history of machine learning and the danger in overhyping what the technology can doThe pros and cons of using end-to-end learning to make predictionsHow releasing machines from preconceptions of what's important helps uncover new scienceWhy understanding the drivers of disease is a critical starting point for developing new interventionsWhy data collection should be part of the fabric of every biopharma companyHow Daphne's work in machine learning can be used to improve clinical trialsWhy now is the right time for a company like InsitroHow Daphne thinks about privacy and issues of informed consent Connect with Daphne KollerInsitro Connect with Dr. Gautam GulatiHLTHDr. G. on LinkedInDr. G. on Twitter ResourcesCourseraArt Levinson at CalicoDr. Hal Barron at GSKAducanumabChasing My Cure: A Doctor's Race to Turn Hope into Action by David FajgenbaumInsitro's Partnership with GileadUK Biobank Introductory Quote[5:34] “What I really wanted to build was a company that rethought drug discovery and development from the ground up, using machine learning as a foundational tool.”

Meet Daphne Koller, Ph.D.:Daphne Koller, Ph.D. is the founder and CEO of insitro, a company that aims to improve drug discovery and development through machine learning. She is also a co-founder and board member for Engageli. Previously, Dr. Koller co-founded Coursera and served as the co-CEO, President, and eventually co-Chairman. She was also the Chief Computing Officer for CalicoLabs. Dr. Koller earned her Ph.D. in Computer Science at Stanford University and taught there as a professor for 18 years. Key Insights:Dr. Koller is “bilingual” in the worlds of biomedicine and machine learning. She has had a diverse career in academia, industry, and entrepreneurism.Two Worlds. At insitro, Dr. Koller brings together the two worlds of machine learning and biomedicine. Machine learning understands the capabilities of what data can provide, and biomedicine understands the insights that can be extracted. Working together can not only solve problems, but reveal new questions. (7:27)Science as a Team Sport. Dr. Koller contrasts academia's focus on the individual researcher with industry's focus on organizational growth and teamwork. She emphasizes the importance of releasing one's ego and creating a whole that is larger than the sum of the parts. (22:16)The Right Team. It is important for founders to build the right team around them. The executive leadership needs to have the ability to strategize and shape the vision, as well as be equipped with industry expertise. From day one, be deliberate about culture and creating alignment. (25:03)This episode is hosted by Suchi Saria, Ph.D. She is a member of the Advisory Council for Day Zero and is the founder and CEO of Bayesian Health. She is also an Associate Professor of computer science, statistics, and health policy, and the Director of the Machine Learning and Healthcare Lab at Johns Hopkins University.Relevant Links:Learn more about insitroTake one of Dr. Koller's courses on CourseraFollow Dr. Koller on Twitter

How does collaboration between machine learning and biomedicine spur AI innovation? How can these two scientific cultures compliment and support one another? In this AI Ignition episode, Daphne Koller, Founder and CEO of Insitro and Co-founder of Coursera, discusses her vision and experience drawing on the best of both disciplines to create value.

Daphne Koller is the CEO and founder of insitro, a machine learning-enabled drug discovery company. Previously, she was a professor of computer science at Stanford University for 18 years, co-founder and co-CEO of Coursera, and the Chief Computing Officer of Calico, an Alphabet company in the healthcare space. She received the MacArthur Foundation Fellowship in 2004. In this conversation with Stanford adjunct lecturer Ravi Belani, Koller examines the key turning points in her diverse and innovative career, and speaks about how she searched for the opportunities that would have the greatest impact on the world.

Daphne Koller is the CEO and founder of insitro, a machine learning-enabled drug discovery company. Previously, she was a professor of computer science at Stanford University for 18 years, co-founder and co-CEO of Coursera, and the Chief Computing Officer of Calico, an Alphabet company in the healthcare space. She received the MacArthur Foundation Fellowship in 2004. In this conversation with Stanford adjunct lecturer Ravi Belani, Koller examines the key turning points in her diverse and innovative career, and speaks about how she searched for the opportunities that would have the greatest impact on the world.

AI research wunderkind, DeepMind, has long been all fun and games. The London-based organization, owned by Google parent company Alphabet, has used deep learning to train algorithms that can take down world champions at the ancient game of Go and top players of the popular strategy video game Starcraft. Then last year, things got serious when DeepMind trounced the competition at a protein folding contest. Predicting the structure of proteins, the complex molecules underpinning all biology, is notoriously difficult. But DeepMind's AlphaFold2 made a quantum leap in capability, producing results that matched experimental data down to a resolution of a few atoms. In July, the company published a paper describing AlphaFold2, open-sourced the code, and dropped a library of 350,000 protein structures with a promise to add 100 million more. This week, Alphabet announced it will build on DeepMind's AlphaFold2 breakthrough by creating a new company, Isomorphic Labs, in an effort to apply AI to drug discovery. “We are at an exciting moment in history now where these techniques and methods are becoming powerful and sophisticated enough to be applied to real-world problems including scientific discovery itself,” wrote Demis Hassabis, DeepMind founder and CEO, in a post announcing the company. “Now the time is right to push this forward at pace, and with the dedicated focus and resources that Isomorphic Labs will bring.” Hassabis is Isomorphic's founder and will serve as its CEO while the fledgling company gets its feet, setting the agenda and culture, building a team, and connecting the effort to DeepMind. The two companies will collaborate, but be largely independent. “You can think of [Isomorphic] as a sort of sister company to DeepMind,” Hassabis told Stat. “The idea is to really forge ahead with the potential for computational AI methods to reimagine the whole drug discovery process.” While AlphaFold2's success sparked the effort, protein folding is only one step—arguably simpler than others—in the arduous drug discovery process. Hassabis is thinking bigger. Though details are scarce, it appears the new company will build a line of AI models to ease key choke points in the process. Instead of identifying and developing drugs themselves, they'll sell a platform of models as a service to pharmaceutical companies. Hassabis told Stat these might tackle how proteins interact, the design of small molecules, how well molecules bind, and the prediction of toxicity. That the work will be separated from DeepMind itself is interesting. The company's not insignificant costs have largely been dedicated to pure research. DeepMind turned its first profit in 2020, but its customers are mostly Alphabet companies. Some have wondered if it'd face more pressure to focus on commercial products. The decision to create a separate enterprise based on DeepMind research seems to indicate that's not yet the case. If it can keep pushing the field ahead as a whole, perhaps it makes sense to fund a new organization—or organizations, seeded by future breakthroughs—as opposed to diverting resources from DeepMind's more foundational research. Isomorphic Labs has plenty of company in its drug discovery efforts. In 2020, AI in cancer, molecular, and drug discovery received the most private investment in the field, attracting over $13.8 billion, more than quadruple 2019's total. There have been three AI drug discovery IPOs in the last year, and mature startups—including Exscientia, Insilico Medicine, Insitro, Atomwise, and Valo Health—have earned hundreds of millions in funding. Companies like Genentech, Pfizer, and Merck are likewise working to embed AI in their processes. To a degree, Isomorphic will be building its business from the ground up. AlphaFold2 is without a doubt a big deal, but protein modeling is the tip of the drug discovery iceberg. Also, while AlphaFold2 had the benefit of access to hundreds of thousands of freely available, already modeled protein s...

DLA Piper partners Ellen Scordino and Susan Krumplitsch are joined by Duane Valz, General Counsel of Insitro, to discuss how machine learning is being used to generate and leverage data for the development of better medicines.

Vijay Pande is a General Partner @ Andreessen Horowitz (a16z), where he focuses on investments in Biopharma & Healthcare. As the founding investor of a16z's Bio Fund, Vijay leads the firm's investments at the cross section of biology and computer science, including applications in computation, machine learning, and artificial intelligence in healthcare; digital therapeutics; diagnostics; and other novel transformative scientific advances applied to industry that take bio beyond healthcare. Op-eds by Vijay defining trends and issues in this emerging space have been published by The New York Times, Scientific American, and Forbes, among others. He is also an Adjunct Professor of Bioengineering at Stanford University.Previously, Vijay was the Henry Dreyfus Professor of Chemistry and Professor of Structural Biology and of Computer Science at Stanford University, where he led a team of researchers pioneering computational methods and their application to medicine and biology (resulting in over 300 publications, two patents, and two novel drug candidates). Vijay was also concurrently the director of the Biophysics program at Stanford, where he led a team of more than 50 faculty members and propelled the program to the top in the country.During his time at Stanford, Vijay co-founded Globavir Biosciences, where he translated his research advances into a successful startup that aimed to discover cures for Dengue Fever and Ebola. Vijay also founded the Folding@Home Distributed Computing Project for disease research, which pushed the boundaries of computer science techniques (distributed systems, machine learning, and exotic computer architectures) into biology and medicine, in both research as well as the development of new therapeutics.Vijay holds a BA in Physics from Princeton University and a PhD in Physics from MIT. He has been awarded the DeLano Prize in Computation; a Guinness World Record for Folding@Home; the American Chemical Society Thomas Kuhn Paradigm Shift Award; and was selected for MIT TR10. In his teens, Vijay was the first employee at video game startup Naughty Dog Software, maker of Crash Bandicoot.Vijay serves on the board of the following Andreessen Horowitz portfolio companies: Apeel Sciences, BioAge Labs, Ciitizen, Devoted Health, Freenome, Insitro, Nautilus Biotechnology, Omada Health, Scribe Therapeutics, and Q Bio.Thank you for listening!BIOS (@BIOS_Community) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures (@AlixVentures) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.Music: Danger Storm by Kevin MacLeod (link & license)

Does the digital health startup you are thinking of investing in, and that is what you are doing when you partner or purchase their product have enough cash to get off the ground?FTAIn the first half of the year, companies raised a total of $14.7 billion across 372 deals, according to a report released today by Rock Health. By comparison, they raised $14.6 billion in 2020 — a record for the time —  and just $7.7 billion in 2019.Some of the biggest funding rounds so far this year include:Diet app Noom, which raised $540 million in MayDirect-to-consumer startup Ro, which raised $500 million in March Drug discovery startup Insitro, which raised $400 million in MarchWhile more companies continued to line up for big exits, the picture looks a little bit different than it did earlier this year.Digital health companies that recently went public haven't performed as well recently as their predecessors.  Of the 18 digital health companies that went public on the New York Stock Exchange and the Nasdaq since the beginning of 2020, their average stock returns fell below Nasdaq levels in the second quarter, according to the report. Meanwhile, those that went public before the pandemic generally performed on-par or better than the Nasdaq average.  Digital health companies that went public in 2020 or 2021 performed worse than the Nasdaq average in recent months, according to Rock Health.---Cash if fuel in the startup world.  The runway for these digital health startups is long.  Does your startup have enough fuel to get off the ground?#heatlhcare #healthIT #cio #cmio #chime #himss https://medcitynews.com/2021/07/digital-health-companies-smash-another-funding-record-raising-14-7b-this-year/

This is the last episode of Season 1. Join us in the Fall for Season 2, and in the meantime, please take our brief survey! http://bit.ly/theaihealthpodcastDr. Daphne Koller is CEO and Founder of insitro, a machine-learning enabled drug discovery company. She has been a Stanford CS Professor, co-founder of Coursera and Engageli, one of TIME Magazine's 100 influential people, and a MacArthur Fellow. She speaks with us about how insitro uses AI and induced pluripotent stem cells to make drug discovery more efficient and successful.Pranav and Adriel first give an overview on pluripotent stem cells. The interview with Dr. Koller starts at 5:41. If you like what you hear, let a friend know, subscribe wherever you get your podcasts, and connect with us on Twitter @AIHealthPodcast.

What does a hybrid team working at the interface of machine learning and biomedicine look like? In this episode, I chat with Daphne Koller, Founder and CEO of insitro, about a data-first approach to drug discovery, building the systems that enable large-scale learning, and the importance of a bilingual culture in "digital biology". Check out the glossary of terms, definitions, and resources (and get a sneak peak of the future conversations lined up!) here: bit.ly/datapulse-glossary --- Support this podcast: https://anchor.fm/the-data-pulse/support